QEQ-278 is under clinical development by Novartis and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QEQ-278’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QEQ-278 is under development for the treatment of solid tumors including non small cell lung cancer, renal cell carcinoma, esophageal squamous cell carcinoma and human papilloma virus associated head and neck squamous cell carcinoma. It is administered through intravenous route. The drug candidate acts by targeting NKG2DL.
For a complete picture of QEQ-278’s drug-specific PTSR and LoA scores, buy the report here.